Fidelity OTC Portfolio Outperforms NASDAQ Composite Amid AI Surge
Finance

Fidelity OTC Portfolio Outperforms NASDAQ Composite Amid AI Surge

authorBy Fareed Zakaria
DateAug 18, 2026
Read time2 min

The Fidelity OTC Portfolio has showcased remarkable financial performance in the recent quarter, significantly surpassing its benchmark, the NASDAQ Composite Index. This impressive showing highlights the effectiveness of its investment philosophy, which centers on identifying and investing in fast-growing companies, predominantly those listed on the Nasdaq exchange. The fund's strategic focus on enterprises driven by innovation, particularly in sectors like artificial intelligence, has yielded substantial returns, reinforcing investor confidence.

During the second quarter, the Retail Class shares of the Fidelity OTC Portfolio recorded an impressive gain of 32.96%. This figure comfortably exceeded the 21.60% advance achieved by its benchmark, the NASDAQ Composite Index, underscoring the fund's superior performance. This period was characterized by a robust U.S. stock market, largely propelled by extensive investments in artificial intelligence technologies. Such spending not only diversified corporate earnings growth but also alleviated concerns regarding a potential economic deceleration, contributing to a favorable market environment for growth-oriented funds.

The investment methodology of the Fidelity OTC Portfolio is built upon a meticulous selection process. It prioritizes companies that exhibit a strong potential for above-average earnings growth and possess sustainable business models. This discerning approach allows the fund to capture opportunities presented by rapidly evolving industries and market trends. By concentrating on dynamic growth companies primarily found on the Nasdaq exchange, the portfolio aims to leverage the innovative spirit and expansion capabilities inherent in these enterprises. The recent quarter's results serve as a testament to the efficacy of this strategy, demonstrating its capacity to generate significant alpha for investors.

The stellar performance of the Fidelity OTC Portfolio in the second quarter, significantly outperforming the NASDAQ Composite Index, can be directly linked to its focused investment strategy. By targeting dynamic growth companies, especially those capitalizing on the artificial intelligence boom, the fund successfully navigated a buoyant market driven by technological advancements and positive economic indicators.

More Articles
Finance
Understanding ETF Liquidations: What Investors Need to Know
Exchange-Traded Funds (ETFs) have become a popular investment vehicle, but they are not immune to closure. This guide explores the reasons behind ETF liquidations, how the process works, and how investors can identify ETFs at risk. It also touches on the tax implications of liquidation and offers advice on managing distributions. Understanding these aspects is crucial for protecting your investments and making informed decisions.
By Mariana MazzucatoAug 18, 2026
Finance
Pagaya Technologies: Sustained Growth and Operational Efficiency Bolster Strong Buy Rating
This analysis reaffirms a "Strong Buy" rating for Pagaya Technologies (PGY), adjusting the price target to $67 due to increased share count and net debt. Pagaya's Q2 2026 results demonstrate the effectiveness of its AI-powered lending platform, marked by a 33% increase in network volume and a 43% rise in adjusted EBITDA. These figures highlight the company's expanding operating leverage and scalable profitability, despite identified risks such as retained credit exposure and potential FRLPC margin compression. The current 15x forward EV/EBITDA multiple is deemed appropriate given the robust operational performance.
By Strive MasiyiwaAug 18, 2026
Finance
U.S. Equity Market Dynamics and Factor Investing in 2026
The initial seven months of 2026 saw strong U.S. equity performance, despite underlying economic uncertainties. The S&P 500 Momentum Index significantly outperformed, reflecting a high-dispersion market. A negative correlation between the S&P 500 Low Volatility and Momentum Indices suggests diversification benefits, with a 50/50 blend showing superior returns and lower volatility over 30 years.
By Morgan HouselAug 18, 2026
Finance
Artiva Biotherapeutics: Pioneering NK Cell Therapy for Autoimmune Diseases
Artiva Biotherapeutics is making significant strides with its off-the-shelf natural killer (NK) cell therapy, AlloNK, targeting refractory rheumatoid arthritis (RA) and other B-cell autoimmune diseases. Early basket studies have shown promising efficacy and a favorable safety profile, with a 71% ACR50 response in RA patients and no serious adverse events linked to the therapy. The company plans to initiate a Phase 3 RA trial in the second half of 2026, with pivotal data anticipated by the second half of 2028, aiming to capture a substantial domestic market opportunity in fourth-line RA.
By David RubensteinAug 18, 2026
Finance
UK Job Market Weakness Persists Despite Economic Growth, Bank of England Rate Cuts Expected in 2027
Despite recent indications of economic recovery in the UK, the labor market continues to show significant weakness, particularly in private sector hiring and wage growth. This persistent softness in employment metrics suggests a high bar for any interest rate hikes by the Bank of England in the near future, unless a severe and prolonged surge in energy prices occurs. Analysts anticipate the Bank of England will maintain current interest rates throughout the remainder of this year, with a projected resumption of rate cuts commencing in the spring of 2027. Consumer-facing industries, such as hospitality and retail, are notably shedding jobs at an accelerating pace.
By David RubensteinAug 18, 2026